LISTED biotech company Actinogen Medical has raised $5.28m through a placement to investors, fully funding the completion of XanADu, Actinogen's Phase II trial of Xanamen in Alzheimer's disease (AD).
The study, approved by the FDA in Jan this year, will enrol 174 patients across the US, UK and Australia, with results expected by Jun 2019.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Nov 17
